ElectromeElectrome home
Buy ActiPatch®
Electrome · Evidence

Knee Osteoarthritis

Randomized and comparative evidence for PEMF / pulsed shortwave therapy in knee and cervical osteoarthritis.

publication

Pulsed Electromagnetic Fields in Knee Osteoarthritis: A Double-Blind Placebo-Controlled Randomized Clinical Trial

Randomized double-blind placebo-controlled trial (n=60) of wearable PEMF therapy worn 12 hours/day for one month in symptomatic knee OA.

View source
publication

Pulsed Shortwave Therapy in Cervical Osteoarthritis: an NSAID-Controlled Randomized Clinical Trial

Randomized parallel-arm trial comparing wearable PSWT against COX-2 NSAID therapy over four weeks; PSWT group showed superior NDI/VAS improvement and zero adverse events.

View source
Educational summary only. Not medical advice. Individual results vary. Consult a qualified healthcare provider before making treatment decisions. ActiPatch® is FDA-cleared (K192234) for musculoskeletal pain; RecoveryRx® is FDA-cleared (K190251) for adjunctive treatment of postoperative pain. Study outcomes such as edema reduction are evidence findings, not additional cleared indications. Both devices are developed and manufactured by BioElectronics Corporation and marketed by Electrome under an exclusive license.